What are the differences between Menotropin (human menopausal gonadotropin) and urofollitropin (recombinant follicle‑stimulating hormone) injections?

Menotropin vs Urofollitropin: Key Compositional and Clinical Differences

Menotropin (human menopausal gonadotropin/hMG) contains both FSH and LH activity in equal amounts, while urofollitropin is purified FSH with minimal to no LH activity 1, 2.

Compositional Differences

Menotropin is a urinary-derived preparation containing:

• Equal amounts of FSH and LH activity (typically 75 IU of each per vial)
• Both gonadotropins extracted from postmenopausal women's urine
• Provides dual hormonal stimulation 2

Urofollitropin (also called highly purified FSH or hp-FSH) contains:

• Purified FSH only
• Minimal to negligible LH activity
• Also urinary-derived but undergoes additional purification to remove LH 3

Clinical Implications

When LH Activity Matters

Women with functional hypothalamic amenorrhea (FHA) or hypogonadotropic hypogonadism specifically require both FSH and LH activity for optimal response 4. In these populations with absent endogenous LH, urofollitropin (FSH-only) produces inadequate estradiol responses 4. For these patients, menotropin is the superior choice.

In Standard IVF/ICSI Cycles

For women with normal ovarian function undergoing assisted reproduction:

• Oocyte yield: Urofollitropin/recombinant FSH produces higher total oocyte numbers 2, 5
• Mature oocyte ratio: No significant difference between menotropin and urofollitropin 6
• Pregnancy rates: Menotropin shows slightly higher clinical pregnancy rates in some meta-analyses (22% higher relative risk with long GnRH agonist protocols) 7, though other studies show equivalence 8, 6
• Embryo quality: Menotropin improves implantation rates and embryo numbers 5

Pharmacokinetic Differences

Both preparations show similar absorption profiles when given subcutaneously 3:

• Peak FSH levels (Cmax): 4.98-7.50 IU/L after single 300 IU dose
• Half-life: 39-53 hours
• Bioavailability: Equivalent between subcutaneous and intramuscular routes

Dosing Considerations

Urofollitropin typically requires:

• Shorter stimulation duration (4.7 vs 5.1 days) 9
• Lower total gonadotropin dose (348 vs 387 IU) 9

Menotropin may be preferred when:

• Patient has low endogenous LH (FHA, hypogonadotropic hypogonadism, hypopituitarism)
• Using GnRH agonist long protocol (where endogenous LH is maximally suppressed)
• Optimizing embryo quality and implantation rates are priorities

Safety Profile

Both medications carry similar risks 1, 8:

• Ovarian hyperstimulation syndrome (OHSS)
• Multiple pregnancy
• Ovarian torsion
• Thromboembolic events

Critical caveat: The presence of LH activity in menotropin does not increase OHSS risk compared to FSH-only preparations when used appropriately 8.

Practical Selection Algorithm

1. Assess endogenous LH status:

   • If absent/severely suppressed (FHA, Kallmann syndrome, deep GnRH agonist suppression) → Choose menotropin
   • If normal ovarian function → Either preparation acceptable

2. Consider protocol:

   • GnRH agonist long protocol with complete pituitary suppression → Menotropin may be advantageous 4
   • GnRH antagonist or PPOS protocols → Either preparation equivalent 6

3. Prioritize outcome:

   • Maximum oocyte yield → Urofollitropin
   • Embryo quality/implantation → Menotropin 5
   • Cost-effectiveness with shorter duration → Urofollitropin 9

The fundamental distinction is that menotropin provides both FSH and LH activity, making it essential for patients lacking endogenous LH, while urofollitropin provides FSH-only stimulation suitable for women with intact LH production.